Reports of molecular and cellular imaging using computed tomography (CT) are rapidly increasing. Many of these reports use gold nanoparticles. Bismuth has similar CT contrast properties to gold while being approximately 1000-fold less expensive. Herein we report the design, fabrication, characterization, and CT and fluorescence imaging properties of a novel, dual modality, fluorescent, polymer encapsulated bismuth nanoparticle construct for computed tomography and fluorescence imaging. We also report on cellular internalization and preliminary in vitro and in vivo toxicity effects of these constructs. 40 nm bismuth(0) nanocrystals were synthesized and encapsulated within 120 nm Poly(DL-lactic-co-glycolic acid) (PLGA) nanoparticles by oil-in-water emulsion methodologies. Coumarin-6 was co-encapsulated to impart fluorescence. High encapsulation efficiency was achieved ~ 70% bismuth w/w. Particles were shown to internalize within cells following incubation in culture. Bismuth nanocrystals and PLGA encapsulated bismuth nanoparticles exhibited >90% and >70% degradation, respectively, within 24 hours in acidic, lysosomal environment mimicking media and both remained nearly 100% stable in cytosolic/extracellular fluid mimicking media. µCT and clinical CT imaging was performed at multiple X-ray tube voltages to measure concentration dependent attenuation rates as well as to establish the ability to detect the nanoparticles in an ex vivo biological sample. Dual fluorescence and CT imaging is demonstrated as well. In vivo toxicity studies in rats revealed neither clinically apparent side effects nor major alterations in serum chemistry and hematology parameters. Calculations on minimal detection requirements for in vivo targeted imaging using these nanoparticles are presented. Indeed, our results indicate that these nanoparticles may serve as a platform for sensitive and specific targeted molecular CT and fluorescence imaging.
INTRODUCTION
High atomic number (Z) metal nanocrystals are recognized for their potential to move computed tomography (CT) from a mostly structural imaging paradigm into a molecular imaging modality [1] [2] [3] [4] , particularly if coupled with emerging spectral CT methodologies [5] [6] [7] [8] . The field is reviewed in Cormode, et al 9 .
Gold nanoparticles (Z = 79, k-edge = 80.7 keV) are the most well developed nanoparticle platform, however the cost of gold may be prohibitive for widespread use. Bismuth nanoparticles (Z = 83, k-edge = 90.5 keV) are a cost effective alternative with potentially equal CT contrast/biocompatibility to gold. Further, bismuth compounds are biodegradable and biocompatible with a long history in biomedicine.
To date, most investigations centering on the use of bismuth for nanoparticulate CT agents have used Bi 2 S 3 as the payload, formulating hydrophilic nanoparticles by using surfactant-based coatings 10, 11 . While excellent size control of nanocrystals has recently been reported 12 , one disadvantage of Bi 2 S 3 is the reduction in the mass percent of bismuth in the formula unit to 80%. Furthermore, the density of Bi 2 S 3 is 6.78 g/ml while that of pure bismuth is 9.78 g/ml, a 31% decrease. Combining these two percentages (80% x 69%) yields 55% decrease in the concentration of bismuth in Bi 2 S 3 versus elemental bismuth. An alternative formulation has incorporated organometallic bismuth neodecanoate complexes into nanoemulsions, again resulting in a relatively low bismuth loading density 13 . A third nanoparticle formulation has incorporated ~ 20 nm elemental bismuth nanocrystals within 130 nm dextran particles 14 . This packing is similar to ferumoxides, an iron oxide nanoparticle for MRI, and inefficiently packages bismuth by volume, with the bismuth payload forming only 0.3% of the total volume.
CT suffers from inherently poor sensitivity, with minimal detection concentrations in the millimolar range 15 . As such, to facilitate molecular and cellular CT, a premium must be placed on efficient delivery and packaging of CT dense contrast material. Herein we describe the design, synthesis, characterization, and ex vivo CT and fluorescence imaging of novel fluorescent, Poly(DL-lactic-co-glycolic acid) (PLGA) encapsulated bismuth nanoparticles for dual CT/fluorescence applications. These particles build on previously reported technology that has been used to form PLGA encapsulated iron oxide 16, 17 , manganese oxide 18 and gadolinium oxide nanoparticles 19 . This platform has been shown to incorporate high payloads of inorganic nanocrystals via a facile oil-in-water emulsion approach. The major innovations in the use of bismuth-based CT nanoparticles are: 1) the use of elemental bismuth nanocrystals for higher contrast density, rather than Bi 2 S 3 , 2) the encapsulation of nanocrystals within an FDA approved polymer, 3) very simple and scalable encapsulation process, and 4) high encapsulation efficiency, resulting in high weight percent of internalized bismuth.
MATERIALS AND METHODS

Bismuth Nanocrystal Synthesis
Bismuth nanocrystals were synthesized according to Son 
Bismuth Nanocrystal Characterization
X-ray diffraction patterns (D8 Advance diffractometer, Bruker Corporation, Billerica, MA) were matched with library of diffraction patterns to determine molecular identity as bismuth(0) 12, 20 . Fourier transform infrared spectroscopy (FTIR) was performed on a Mattson
Genesis 3025 FTIR spectrometer to verify that DDT was present on the bismuth nanocrystals.
Nanocrystals were imaged with transmission electron microscopy (TEM) using a JEOL 2200FS Transmission Electron Microscope (JEOL Ltd, Tokyo, Japan). Nanocrystal size (average +/-SD) was determined by ImageJ (http://rsbweb.nih.gov/ij/) analysis of TEM images.
Nanocrystal Encapsulation in PLGA nanoparticles
Prior to encapsulation, bismuth nanocrystals were incubated at room temperature in oleic acid for 24 hours (1 mL oleic acid per 200 mg bismuth). Nanocrystals were then washed twice with 2 ml ethanol to remove excess oleic acid.
The PLGA encapsulation method was based on that reported by Granot, et al 16 . A stock solution of Poly(DL-lactic-co-glycolic acid) (PLGA) was made by dissolving 1 gram of PLGA in 20 mL dichloromethane (DCM) overnight. Separate solutions of 5% (5 g in 100 mL) and 0.3% (0.3 g in 100 mL) polyvinyl alcohol (PVA) in deionized water were prepared.
To fabricate particles, 2 mL PLGA polymer solution was first placed in a small test tube.
Between 10-200 mg of nanocrystals were then added along with 500 µL of a 2 mg/mL DCM solution of coumarin-6 to enable fluorescent labeling. The mixture was then bath sonicated and vortexed to disperse the nanocrystals. The organic mixture was then added drop-wise to 4 mL 5% PVA solution while vortexing at high speed. The mixture was then vortexed for an additional 10 seconds. The test tube was then tip sonicated three times at 40% amplitude for ten seconds each time to create an oil-in-water emulsion. The test tube was placed in an ice bath between each sonication. After the third tip sonication, the tube's contents were poured into a 60 mL 0.3% PVA solution. The mixture was then stirred with an overhead stirrer for 3 hours to allow nanoparticle formation and DCM evaporation. The nanoparticles were washed 3 times with 20 mL portions of deionized water and collected by centrifugation (17,000 g for 10 minutes). The nanoparticles were then re-suspended in 1 mL deionized water, flash frozen in liquid N 2 , and lyophilized.
Nanoparticle Characterization
Nanoparticle formation was analyzed and diameter was measured (average +/-SD) by scanning electron microscopy (SEM) using an AURIGA® CrossBeam Dual Column SEM-FIB Workstation (Carl Zeiss, Jena, Germany). Bismuth content and encapsulation efficiency was determined by thermogravimetric analysis (TGA) using a Q500 TGA from TA instruments (New Castle, DE). TEM was performed to determine spatial localization of bismuth nanocrystals within the PLGA particle.
Nanocrystal Dissolution
The dissolution of bare bismuth nanocrystals and bismuth nanocrystals in PLGA nanoparticles was assessed using inductively coupled plasma optical emission spectrometry (Varian, 710-ES ICP-OES). To determine the rate at which bismuth dissolves into phosphate buffer saline (PBS) and sodium citrate, 10 mg of bismuth nanocrystals or 15 mg of particles containing 66% w/w bismuth were suspended in either 1 mL of PBS or 1 mL of sodium citrate (pH 5.5). Microcentrifuge tubes containing the 4 mixtures were sonicated and then maintained on a rotary shaker at 36 °C. The tubes were centrifuged briefly to collect the supernatant sample and the remaining pellet was then resuspended in fresh solution prior to being returned to the oven. Supernatant was collected from samples at 1, 4, 9, 18, and 24 hrs on the first day, every 24 hrs for 2 weeks, and subsequently every week for the remainder of the experiment. After the supernatant for all the desired time points had been collected, all the samples were dried using a heating block and then 1 mL of concentrated nitric acid (69% HNO 3 ) was added to each dried sample. After 48 hrs, samples were diluted with ultrapure water to a final concentration of 2% HNO 3 and then each sample was analyzed in triplicate using ICP-OES.
Cell Labeling and In Vitro Toxicity
For all in vitro assays, STO mouse fibroblasts (ATCC) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum at 37ºC and 5% CO 2 . All cell culture materials are from Life Technologies.
For the cell proliferation assay, STO cells were plated at 100,000 per well in a 24-well plate and allowed to adhere overnight. PLGA encapsulated bismuth nanoparticles were suspended in media at 1 mg Bi/mL, sonicated, and 10-fold dilutions in media were made down to 0.1 µg/mL. 500 µL of nanoparticle solution was added to each well. Controls received fresh media only. After 2 days of co-incubation, the nanoparticle solution was removed and replaced with a mixture of 400 µL media and 40 µL of MTT powder (1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan, Sigma) at 5 mg/mL in PBS. 2 hours later, the media was aspirated and 1 mL of dimethylsulfoxide (DMSO, Fisher) was added to each well. 50 µL was immediately transferred to a 96-well plate and absorbance was measured at 560 nm using a plate reader (SpectraMax 190, Molecular Devices). The absorbance of DMSO-only wells was used to establish a baseline. For each experiment, 3 wells were tested per concentration of bismuth, and the experiment was repeated twice. The optical density measurements were normalized to that of the wells containing cells that were not exposed to the PLGA encapsulated bismuth nanoparticles.
To measure apoptosis and cell viability after incubation with PLGA encapsulated bismuth nanoparticles, a flow cytometry assay was used (Pacific Blue annexin V apoptosis detection kit with 7-AAD, BioLegend). STO cells were plated and allowed to adhere overnight.
The next day, PLGA encapsulated bismuth nanoparticles were suspended in PBS containing Within group differences were assessed using a one-way ANOVA with post-hoc comparisons to the vehicle group (Group 1 or 2) of the same dosing route using Dunnett's procedure to correct for multiple comparisons (GraphPad Prism 5.03). In cases where insufficient data were available for one-way ANOVA assessment, but the vehicle group and one or more dose groups could be analyzed, two-tailed paired or unpaired t-tests were used to evaluate within-group differences. Parameters are reported as group mean ±SE. In all cases, a pvalue of <0.05 was considered significant.
In Vitro and Ex Vivo Sample Preparation for µCT and Clinical CT
In vitro samples of PLGA encapsulated bismuth nanoparticles containing 0, 14, 46, 64, and 143 mM bismuth were prepared in 200µL of 0.5% agarose.
A 90 mM bismuth suspension was prepared using 10.2 mg PLGA encapsulated bismuth nanoparticles (63% w/w bismuth from TGA) in 340µL of di H 2 O for ex vivo imaging in chicken wing forearm. Using a one mL syringe in combination with 26 gauge ½ inch needle, the 90 mM suspension of nanoparticles was injected slowly over the course of 1 minute between the radius and the ulna of a chicken wing forearm. After the injection was complete, the needle was allowed to rest in the injection site for an additional minute prior to removal.
µCT and Clinical CT
In vitro and ex vivo imaging was performed using both µCT and clinical CT scanners, guided using parameters described by Galper, et al 15 . µCT scans were performed on a GE 
RESULTS
Bismuth(0) nanocrystals were synthesized by reduction of bismuth dodecanthiolate 12 .
The average nanocrystal diameter as determined by TEM was 38.0 ± 7.1 nm ( Figure 1A ). We found that temperature control was the single most important parameter in maintaining uniform crystal size as reported in Son, et al 12 . XRD confirmed that the nanocrystals were composed of elemental bismuth ( Figure 1A) , as opposed to a bismuth salt. FTIR confirmed that dodecanethiol (DDT) coated the nanocrystals by the presence of peaks at wavenumbers of 2831 and 2919 cm -1
( Figure 1B) .
Bismuth nanocrystals and coumarin-6 were co-encapsulated into PLGA nanoparticles by a simple oil-in-water emulsion approach, as shown schematically in Figure 2 . The formation of PLGA nanoparticles was confirmed by SEM ( Figure 3A ) and the nanoparticles were determined to have an average diameter of 120.4 ± 37.0 nm. TEM confirmed that bismuth nanocrystals were encapsulated within the core of the PLGA nanoparticles, rather than at or near the surface The dissolution of bismuth nanocrystals, both as bare nanocrystals and encapsulated in PLGA, was studied in solvents representing physiological relevant conditions in vitro.
Specifically, incubation in sodium citrate mimics the post-endocytosis environment of a lysosome with a low pH and the presence of citrate 22, 23 . PBS mimics cytosolic and extracellular pH. As previously reported for PLGA encapsulated iron oxide nanoparticles, the bismuth particles had a similar initial "burst" pattern of dissolution 17 . However, the rate of the dissolution was faster for PLGA encapsulated bismuth nanoparticles than for iron particles, consuming almost 70% of the bismuth nanocrystals in 24 hr ( Figure 6 ). The rate of the initial burst phase This data proved that the nanoparticles retain their contrast generating properties after injection into tissue. However, this result encouragingly points towards the potential of significant accumulations of contrast agent occurring in a tumor or within an atherosclerotic plaque by EPR effect or by targeted delivery. In Figure 9 we present side by side CT and fluorescence images of a tissue sample injected with the nanoparticles. As can be seen, there is excellent co-localization of the fluorescence and CT signal, demonstrating the bimodal imaging functionality of the agent.
MTT assays were performed on cells labeled with particles in vitro. After a one-way ANOVA found that there was a significant effect of bismuth concentration on cell proliferation (p=0.0001), t-tests were performed to determine which values were significantly different from the controls. At 0.0001 mg/mL, 0.001 mg/mL and 0.01 mg/mL, there was no statistically significant effect on proliferation. At the highest concentrations (0.1 mg/mL and 1 mg/mL), there was significantly less cell proliferation than in the controls (Sup Figure 1) .
Flow cytometry was used to measure cells that were either apoptotic and/or dead. Flow cytometry assays for annexin V and 7AAD found that the control cells were 10% doublepositive. Low levels of labeling did not affect cell viability but higher concentrations of bismuth reduced viability. Cells that were incubated with 5 pg/cell of bismuth were 24% double positive, while cells exposed to 150 pg/cell were 36% double positive (Sup Figure 2) .
A rigorous in vivo toxicity study was also performed. The full results are detailed in Supplemental Data. No animals showed any apparent clinical abnormalities, aside from loose stools in a few animals at 24 hours post injection (both IV injected experimental groups) and at day 8 (control group, IP injection).
Some serum chemistry values were altered at both 24 hours and 7 days post-injection.
These alterations were most significantly noted in those animals that received IV administration of the nanoparticles, although some were also noted in the high dose IP injected animals. As expected, these changes are within the pathways for kidney and liver metabolism. Notably, elevation in liver enzymes at 24 hours post injection of particles was fully resolved at 7 days.
Hematology was also examined. At 24-hours post-injection, and at 7 day time point, mean platelet volume (MPV) was statistically increased in the group of animals receiving 20mg/kg IV. The same group had a statistically significant reduction in hematocrit and hemoglobin, with increased white blood cell and lymphocyte counts.
A pathological and histopathological evaluation was performed on one animal from each group. No statistically significant changes in organ weights were noted and no gross changes were identified on necropsy. Mild to moderate BALT hyperplasia was a common finding in nearly every animal, possibly due to mycoplasma infection. In one animal from high dose IV injection, focal regions of alveolar macrophages within alveoli were identified. Occasional pathological findings were observed in spleen, kidney and liver. Of note, one animal from the high dose IV injection showed evidence of regeneration of the kidney following transient injury.
DISCUSSION
In this manuscript we report on the design, fabrication, characterization and extensive in vitro and in vivo assaying of PLGA encapsulated bismuth nanoparticles, which can be utilized as a potential CT contrast agent. The synthetic approach is facile and flexible, permitting one to tailor the approach for encapsulating less bismuth if desired, changing the overall size of the particle and using other hydrophobic polymers for encapsulation.
The toxicological aspects of bismuth preparations are well established and the published side effects of various routes of injection include nephropathy, hepatitis, encephalopathy, gastroenteritis and osteoarthropathy [24] [25] [26] [27] [28] [29] [30] . In this study, although no clinically apparent side effects were noted, several changes were identified on clinicopathological and histopathological evaluation of animals and their internal organs. The group with the most apparent changes was the high dose, 20mg/kg IV group. Histopathological changes in this group included ones suggestive of transient kidney injury and periportal inflammatory process in the liver. These changes correlate with the routes of bismuth excretion from the body 27, 28 . Previous studies have shown that after IV injection of various bismuth preparations the majority of bismuth concentrates in the kidneys 27, 31 . Studies have previously described reversible kidney failure after ingestion of bismuth and characteristic histopathological changes 24, 32 . In this study, characteristic kidney injury affecting tubular epithelial cells was noted in an animal from the 20mg/kg IV group. Regarding clinicopathologic values that may suggest kidney injury, only magnesium levels were significantly lower in this group. Significant reduction of hematocrit may be a result of kidney injury, although eryptosis -an apoptotic death of erythrocytes, is more likely. Bismuth has recently been described as a potential trigger of eryptosis 33 . This metal induces cellular multiple changes characteristic for this process -phosphatydylserine expression on cell surface, decrease in erythrocyte size, increase in intracellular Ca 2+ activity and formation of ceramide leading to erythrocyte death 33 .
Another route of excretion of this heavy metal is via bile, and rarely, liver injury has also been reported after bismuth ingestion 27, 31 . Periportal inflammatory cell infiltrates in the liver were apparent in the 20mg/kg IV group and early (24 hours post particle injection) increase in liver enzymes was significant in this group. Decrease in hemoglobin concentration may be also associated with liver toxicity due to bismuth and how it affects the liver cells and their mitochondria. Concurrent lymphocyte and total white blood cell count increases, and subsequently an increase in globulin and total protein levels, are suggesting an inflammatory response that is probably triggered by bismuth injection.
As mentioned earlier, CT imaging suffers from low sensitivity, with contrast agent accomplished with previous metal oxide nanoparticles [16] [17] [18] [19] 35 . For passive targeting of compromised vascularity due to injury or disease, cryoprotection 35 F is a rotated zoom of boxed region in E. Still intact PLGA encapsulated bismuth nanoparticles can potentially be seen in the endo/lysosome in F. 52x26mm (300 x 300 DPI) 
